Calidi Biotherapeutics (CLDI) Competitors $0.48 +0.00 (+0.10%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CLDI vs. BYSI, KRON, DTIL, IMMX, OKYO, PEPG, IMRX, KPTI, PMVP, and AVTXShould you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include BeyondSpring (BYSI), Kronos Bio (KRON), Precision BioSciences (DTIL), Immix Biopharma (IMMX), OKYO Pharma (OKYO), PepGen (PEPG), Immuneering (IMRX), Karyopharm Therapeutics (KPTI), PMV Pharmaceuticals (PMVP), and Avalo Therapeutics (AVTX). These companies are all part of the "pharmaceutical products" industry. Calidi Biotherapeutics vs. BeyondSpring Kronos Bio Precision BioSciences Immix Biopharma OKYO Pharma PepGen Immuneering Karyopharm Therapeutics PMV Pharmaceuticals Avalo Therapeutics Calidi Biotherapeutics (NYSE:CLDI) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Does the MarketBeat Community prefer CLDI or BYSI? BeyondSpring received 185 more outperform votes than Calidi Biotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformCalidi BiotherapeuticsN/AN/ABeyondSpringOutperform Votes18566.79% Underperform Votes9233.21% Do analysts rate CLDI or BYSI? Calidi Biotherapeutics currently has a consensus target price of $15.00, indicating a potential upside of 3,018.50%. Given Calidi Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Calidi Biotherapeutics is more favorable than BeyondSpring.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00BeyondSpring 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, CLDI or BYSI? BeyondSpring has higher revenue and earnings than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalidi Biotherapeutics$50K273.86-$29.22MN/AN/ABeyondSpring$1.88M38.90-$21.03MN/AN/A Is CLDI or BYSI more profitable? Company Net Margins Return on Equity Return on Assets Calidi BiotherapeuticsN/A N/A -344.45% BeyondSpring N/A N/A N/A Do institutionals and insiders believe in CLDI or BYSI? 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 24.3% of Calidi Biotherapeutics shares are owned by insiders. Comparatively, 29.3% of BeyondSpring shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, CLDI or BYSI? Calidi Biotherapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Does the media favor CLDI or BYSI? In the previous week, Calidi Biotherapeutics had 4 more articles in the media than BeyondSpring. MarketBeat recorded 5 mentions for Calidi Biotherapeutics and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.87 beat Calidi Biotherapeutics' score of 0.29 indicating that BeyondSpring is being referred to more favorably in the news media. Company Overall Sentiment Calidi Biotherapeutics Neutral BeyondSpring Very Positive SummaryBeyondSpring beats Calidi Biotherapeutics on 7 of the 13 factors compared between the two stocks. Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDI vs. The Competition Export to ExcelMetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$13.78M$2.98B$5.53B$19.02BDividend YieldN/A1.89%5.11%4.03%P/E RatioN/A30.6422.6533.12Price / Sales275.57500.06401.9828.04Price / CashN/A168.6838.1817.52Price / Book-0.213.206.754.51Net Income-$29.22M-$72.35M$3.22B$1.02B7 Day Performance-0.37%1.61%1.66%1.38%1 Month Performance-13.12%8.95%4.17%-1.99%1 Year PerformanceN/A-22.19%16.17%5.28% Calidi Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDICalidi Biotherapeutics2.1673 of 5 stars$0.48-0.3%$15.00+3,018.5%N/A$13.69M$50,000.000.0038BYSIBeyondSpringN/A$1.57-1.9%N/A-13.4%$54.02M$1.88M0.0080Positive NewsKRONKronos Bio2.727 of 5 stars$0.89+4.0%$1.63+83.6%-13.3%$53.96M$9.85M-0.62100Upcoming EarningsNews CoverageGap DownTrading HaltedDTILPrecision BioSciences4.3539 of 5 stars$5.11-4.1%$37.67+637.1%-45.8%$53.91M$68.70M85.18200Positive NewsIMMXImmix Biopharma3.3078 of 5 stars$1.94+3.7%$7.00+260.8%-2.8%$53.78MN/A-2.289Upcoming EarningsShort Interest ↓News CoveragePositive NewsOKYOOKYO Pharma2.7725 of 5 stars$1.55+2.6%$7.00+351.6%+5.7%$52.45MN/A0.007Short Interest ↓News CoveragePositive NewsPEPGPepGen2.7911 of 5 stars$1.60+4.6%$10.33+545.8%-87.2%$52.31MN/A-0.5430Positive NewsIMRXImmuneering3.7885 of 5 stars$1.45flat$12.50+762.1%-16.2%$52.18M$320,000.00-0.7460Upcoming EarningsShort Interest ↓News CoveragePositive NewsGap UpKPTIKaryopharm Therapeutics3.6369 of 5 stars$6.07+8.0%$57.50+847.3%-56.3%$52.02M$145.24M-5.95380Upcoming EarningsShort Interest ↑News CoveragePMVPPMV Pharmaceuticals2.2656 of 5 stars$1.00-3.8%$5.67+466.7%-45.0%$51.93MN/A-1.0050Upcoming EarningsNews CoverageGap UpAVTXAvalo Therapeutics3.8893 of 5 stars$4.73-1.0%$33.00+597.7%-70.9%$50.48M$441,000.000.0040News CoverageGap Up Related Companies and Tools Related Companies BeyondSpring Competitors Kronos Bio Competitors Precision BioSciences Competitors Immix Biopharma Competitors OKYO Pharma Competitors PepGen Competitors Immuneering Competitors Karyopharm Therapeutics Competitors PMV Pharmaceuticals Competitors Avalo Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CLDI) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLDI Stock Free CLDI Stock Alerts